drugset / Trial / NCT00239096
Prevention of Decompensation in Liver Cirrhosis
Phase 4
Unknown
100 enrolled
Odense University Hospital
Else Poulsen Mindelegat · collabLundbeck Foundation · collabUniversity of Southern Denmark · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention. Moreover is the purpose to asses whether losartan is antifibrotic.
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Losartan | Other / unclassified | — | — |